CellProthera prepares Phase 3 trial for first-in-class heart repair therapy

CellProthera is advancing its CD34+ stem cell therapy ProtheraCytes toward a pivotal Phase 3 trial targeting patients after myocardial infarction, aiming to prevent progression to heart failure. The company has strengthened its governance with appointments of Jérôme Hirtzlin and Anne de la Fortelle and identifies GMP-compliant production, site selection and operator training as immediate milestones […] The post CellProthera prepares Phase 3 trial for first-in-class heart repair therapy appeared first on Longevity.Technology.